Antony Bigot

USPTO Granted Patents = 22 (Patent Applications = 3)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 2)

Average Co-Inventor Count = 4.3

ph-index = 6

Forward Citations = 151(Granted Patents)

Location History:

Vitry-sur-Seine, FR (2007)
Massy, FR (2002 - 2011)
Paris, FR (2003 - 2021)

Company Filing History:

Sanofi-a Ventis Deutschland Gmbh

The Scripps Research Institute

Years Active: 2002-2021

Loading Chart...

22 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10941139 - Cryptophycin compounds and conjugates, their preparation and their therapeutic use (2021-03-09),

2. 8865906 - Process for the preparation of a compound useful as an inhibitor of TAFIa (2014-10-21),

3. 8314244 - Method for preparing activated esters (2012-11-20),

4. 8207355 - Method for preparing azetidine derivatives (2012-06-26),

5. 8119813 - [object Object] (2012-02-21),

6. 7884123 - Substituted thieno[2,3-c]pyrazoles, process for preparing them, compositions containing them, and use thereof (2011-02-08),

7. 7589117 - Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them (2009-09-15),

8. 7579366 - Epothilone derivatives and their synthesis and use (2009-08-25),

9. 7265111 - Adenosine analogues and their use as pharmaceutical agents (2007-09-04),

10. 7232834 - Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor (2007-06-19),

11. 7232833 - 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them (2007-06-19),

12. 7227022 - Use of 2-amino-thiazoline derivatives as inhibitors of inducible no-synthase (2007-06-05),

13. 7078428 - Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them (2006-07-18),

14. 6953796 - Use of 2-amino-thiazoline derivatives as inhibitors of inducible No-synthase (2005-10-11),

15. 6872740 - Use of 2-amino-4-heteroarylethyl-thiazoline derivatives as inhibitors of inducible no-synthase (2005-03-29),

Title: Antony Bigot: Innovator in Pharmaceutical Patents

Introduction: Antony Bigot is a prolific inventor based in Massy, France, recognized for his substantial contributions to the field of pharmaceuticals. With a remarkable portfolio of 22 patents, he has focused on developing novel compounds and therapeutic applications that aim to improve health outcomes, particularly in oncology.

Latest Patents: Among his most recent innovations are two significant patents. The first pertains to "Cryptophycin compounds and conjugates, their preparation and their therapeutic use." This invention involves cryptophycin compounds with extensive potential as anticancer agents, detailing their preparation processes and therapeutic applications. The second is titled "Process for the preparation of a compound useful as an inhibitor of TAFIa," which describes a method for synthesizing a specific compound aimed at inhibiting TAFIa activity.

Career Highlights: Antony Bigot has worked with renowned companies in the pharmaceutical sector, including Aventis Pharma S.A. and Sanofi-Aventis Deutschland GmbH. His experience in these firms has fostered a deep understanding of drug development and innovation.

Collaborations: During his career, Antony Bigot has collaborated with noted professionals such as Serge Mignani and Jean-Christophe Carry. These partnerships have contributed to advancements in his projects, further elevating the significance of his patent contributions.

Conclusion: Antony Bigot represents a pioneering figure in pharmaceutical innovation, especially with his focus on anticancer therapies. His numerous patents reflect his dedication to improving health outcomes through scientific research and collaboration. With a continuing commitment to invention, he is expected to make further impactful strides in the industry.

This text is generated by artificial intelligence and may not be accurate.